Meropenem - Revision history

Prab: CSV import

2025-03-23T11:01:14Z

CSV import

@@ Line 1: / Line 1: @@
-{{intro}}
+== Meropenem ==
-Meropenem is a carbapenem antibiotic with broad spectrum of activity that is administered intravenously and used for severe bacterial infections due to sensitive agents.
-{{livtox}}
+[[File:Meropenem-from-xtal-1992-3D-balls.png|thumb|left|3D model of Meropenem]]
-{{use}}
+While meropenem is resistant to many beta-lactamases, some bacteria have developed mechanisms to resist its effects. These include the production of [[carbapenemase]] enzymes, which can hydrolyze meropenem, and changes in bacterial [[porin]] channels that reduce drug uptake. The emergence of carbapenem-resistant [[Enterobacteriaceae]] (CRE) is a significant concern in healthcare settings.
-{{fda}}
+== Related Pages ==
-{{dose}}
+* [[Antibiotic resistance]]
-The recommended dosage is 0.5 to 1 gram given intravenously every 8 hours, with dose adjustment for renal impairment.  Meropenem is available in vials of 500 mg or 1 gram of lyophilized powder for injection in generic forms and under the brand name Merrem.
+* [[Beta-lactam antibiotics]]
-{{se}}
+[[File:Meropenem_1.jpg|thumb|right|Vial of Meropenem for injection]]
-{{carbapenems}}
+== Conclusion ==
-{{coststubd}}
-== Meropenem ==
+Meropenem is a powerful antibiotic used to treat severe bacterial infections, particularly those caused by resistant organisms. Its broad-spectrum activity and resistance to many beta-lactamases make it a valuable tool in the fight against bacterial infections. However, the emergence of resistant strains highlights the need for careful use and ongoing research into new antimicrobial agents.
-<gallery>
-File:Meropenem structure.svg|Meropenem structure
+[[Category:Antibiotics]]
-File:Meropenem-from-xtal-1992-3D-balls.png|Meropenem 3D model
+[[Category:Carbapenems]]

Prab: CSV import

2025-02-20T01:24:11Z

CSV import

← Older revision		Revision as of 01:24, 20 February 2025
Line 22:		Line 22:
	{{carbapenems}}		{{carbapenems}}
	{{coststubd}}		{{coststubd}}
			== Meropenem ==
			<gallery>
			File:Meropenem structure.svg\|Meropenem structure
			File:Meropenem-from-xtal-1992-3D-balls.png\|Meropenem 3D model
			File:Meropenem 1.jpg\|Meropenem
			</gallery>
	== Meropenem ==		== Meropenem ==
	<gallery>		<gallery>

Prab: CSV import

2025-02-20T01:21:46Z

CSV import

← Older revision		Revision as of 01:21, 20 February 2025
Line 22:		Line 22:
	{{carbapenems}}		{{carbapenems}}
	{{coststubd}}		{{coststubd}}
			== Meropenem ==
			<gallery>
			File:Meropenem structure.svg\|Meropenem structure
			File:Meropenem-from-xtal-1992-3D-balls.png\|Meropenem 3D model
			File:Meropenem 1.jpg\|Meropenem
			</gallery>

Prab: Created page with "{{intro}} Meropenem is a carbapenem antibiotic with broad spectrum of activity that is administered intravenously and used for severe bacterial infections due to sensitive age..."

2019-04-28T13:24:44Z

Created page with "{{intro}} Meropenem is a carbapenem antibiotic with broad spectrum of activity that is administered intravenously and used for severe bacterial infections due to sensitive age..."

New page

{{intro}}
Meropenem is a carbapenem antibiotic with broad spectrum of activity that is administered intravenously and used for severe bacterial infections due to sensitive agents.

{{livtox}}
Meropenem is a common cause of mild transient aminotransferase elevations and can rarely result in clinically apparent, cholestatic liver injury.

{{moa}}
Meropenem (mer" oh pen' em) is a broad spectrum, beta-lactam carbapenem antibiotic that acts by binding to the penicillin binding proteins and disrupting bacterial cell wall integrity and synthesis.

{{use}}
Meropenem has a broad spectrum of activity against many aerobic and anaerobic gram-positive and gram-negative organisms, including Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis, Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis and Peptostreptococcus species.

{{fda}}
Meropenem was approved for use in the United States in 1996 and is currently indicated for the treatment of severe or complicated skin, tissue, intraabdominal and urogenital infections as well as sepsis due to susceptible organisms. Its use is generally reserved for severe infections in hospitalized patients.

{{dose}}
The recommended dosage is 0.5 to 1 gram given intravenously every 8 hours, with dose adjustment for renal impairment. Meropenem is available in vials of 500 mg or 1 gram of lyophilized powder for injection in generic forms and under the brand name Merrem.

{{se}}
The most common side effects are diarrhea, nausea and vomiting, skin rash and pruritus.

{{carbapenems}}
{{coststubd}}